What Is KPV? KPV (Lys‑Pro‑Val) is a tripeptide fragment derived from the C‑terminal sequence of α‑melanocyte‑stimulating hormone (α‑MSH). It has been studied for its anti‑inflammatory, immunomodulatory, and cytoprotective properties. Unlike full‑length α‑MSH, KPV retains significant biological activity in a smaller, more stable peptide form, making it attractive for therapeutic exploration. Mechanism of Action KPV exerts its effects by modulating inflammatory pathways, including inhibition of pro‑inflammatory cytokines such as TNF‑α, IL‑1β, and IL‑6. It also downregulates NF‑κB signaling, reducing oxidative stress and tissue damage. KPV has been shown to stabilize epithelial barriers, enhance wound healing, and protect against gastrointestinal mucosal injury. Its activity extends to skin and connective tissue, where it supports regeneration and reduces inflammatory responses. Research & Clinical Data Preclinical studies demonstrate KPV’s efficacy in models of colitis, dermatitis, and wound healing. It has been investigated for topical and systemic applications, with promising results in reducing inflammation and accelerating tissue repair. Limited human data exist, but ongoing research explores its potential in dermatology, gastroenterology, and regenerative medicine. Regulatory approval has not yet been established, and KPV remains investigational. Purity & Quality Reference‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: investigational, not FDA‑ or EMA‑approved. Classification & Handling Class: Tripeptide fragment of α‑MSH | Source: Endogenous melanocortin peptide | Administration: Topical or parenteral (investigational) | Storage: 2–8°C refrigerated, protect from light | Regulatory: Not FDA/EMA approved